表紙
市場調查報告書
商品編碼
252361

靜脈注射免疫球蛋白 (IVIg) 的全球市場

Intravenous Immunoglobulin (IVIg)

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 222 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球靜脈注射免疫球蛋白(IVIg)市場相關調查、各地區趨勢、2013年∼2020年的預測、市場參與企業簡介等彙整資料。

第1章 簡介、調查方法、產品定義

第2章 摘要整理

  • 產業概要
    • 靜脈注射免疫球蛋白
    • FDA已經過核准及非標籤藥物的靜脈注射免疫球蛋白治療方法清單
    • 各地區市場
    • 推動成長要素和市場課題
    • 競爭模式
    • 全球大企業所提供的IVIg產品
  • 市場趨勢
  • 血漿蛋白質:概要
  • 治療概要
    • 免疫球蛋白概要
    • IVIg和SCIg
    • 產品及治療的成本
    • 副作用
    • 治療頻率
    • 安全性
    • 患者對治療的反應
    • 治療部位
    • IVIg治療的簡介
    • 血管內免疫球蛋白
    • IVIg作用機制 其他
  • 法律上的認證
  • 產品創新/引進
  • 近幾年的產業活動
  • 全球參與企業
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
  • 亞太地區
    • 澳洲
    • 中國
目錄
Product Code: MCP-7776

Abstract:

Global Intravenous Immunoglobulin (IVIg) Market to Reach $15.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Intravenous Immunoglobulin (IVIg) estimated at US$10.3 Billion in the year 2020, is projected to reach a revised size of US$15.7 Billion by 2027, growing at a CAGR of 6.2% over the analysis period 2020-2027. IgA, one of the segments analyzed in the report, is projected to record a 6.8% CAGR and reach US$5.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the IgD segment is readjusted to a revised 6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3 Billion, While China is Forecast to Grow at 5.8% CAGR

The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.9% and 4.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5% CAGR.

IgE Segment to Record 6.4% CAGR

In the global IgE segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$2.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.8 Billion by the year 2027.

Select Competitors (Total 24 Featured) -

  • Bharat Serums and Vaccines Limited
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Kedrion S.p.A.
  • LFB Group
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire plc
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Immunoglobulins to See Steady Growth
    • Recent Market Activity
    • Intravenous Immunoglobulin - A Proliferating Biologic
    • Application Areas - A Brief Review
    • Market Outlook
    • Growth Drivers and Market Challenges
    • Competitive Scenario
    • Grifols Continues to Consolidate Market Position
    • Comparison of Select Drugs and Approved Indications
    • CSL Sees Robust Growth in Immunoglobulin Franchise
    • Shire Continues to Invest Big in Immunoglobulins
    • Bivigam Changes Hands Consequent to Unexpected Turn of Events
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Bharat Serums and Vaccines Limited (India)
    • Biotest AG (Germany)
    • China Biologic Products, Inc. (China)
    • Guizhou Taibang Biological Products Co., Ltd (China)
    • CSL Limited (Australia)
    • Grifols, S.A. (Spain)
    • Hualan Biological Engineering Inc. (China)
    • Kedrion S.p.A. (Italy)
    • LFB Group (France)
    • Octapharma AG (Switzerland)
    • Shanghai RAAS Blood Products Co., Ltd. (China)
    • Shire plc (Ireland)
    • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
  • 3. MARKET TRENDS & DRIVERS
    • Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
    • Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
    • IVIg - The Mainstay of PI Therapy
    • Subcutaneous IG Formulations Gain Therapeutic Foothold
    • Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead
    • Unsuccessful Clinical Trials for Alzheimer's - A major Setback for IVIg Market
    • Synthetic Replacements to IVIg Therapy
    • IVIg Therapy - Home-based vs. Outpatient Settings
    • Per Capita Consumption Rate Varies Across Countries
    • Favorable Reimbursement and High Usage make US the Largest Consumer
    • Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
    • Aging Global Population: Major Opportunity Indicator
    • Improving Healthcare Expenditure to Foster Growth

IV. COMPETITION

  • Total Companies Profiled: 24